Know Cancer

forgot password

Phase II Trial of Vinflunine Plus Trastuzumab in HER2 Over-Expressing Metastatic Breast Cancer

Phase 2
18 Years
Not Enrolling
Breast Neoplasms, Breast Cancer

Thank you

Trial Information

Phase II Trial of Vinflunine Plus Trastuzumab in HER2 Over-Expressing Metastatic Breast Cancer

If the tumor is HER2neu positive, eligible patients will receive trastuzumab and vinflunine
intravenously (IV) every 3 weeks.

If the tumor is HER2neu negative, eligible patients will receive vinflunine intravenously
(IV) every 3 weeks.

Patients whose cancer does not grow or decreases in size may continue to receive treatment
until cancer progression. Evaluation of cancer will be every 9 weeks.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed breast cancer with
metastatic disease. Patients without pathologic or cytologic confirmation of
metastatic disease should have unequivocal evidence of metastasis using the RECIST

- The HER2 status of the tumor will be used to stratify patients. Tumors that are HER2
FISH+ will receive vinflunine and trastuzumab. Patients with tumors which are HER2
FISH negative or if the HER2 status is unknown/not performed will remain on study and
will receive single agent vinflunine. HER2 positivity based on IHC testing (2+ or
3+) must be confirmed by FISH testing. If a patient's tumor scores IHC 2+ or 3+ and
is found to be FISH negative, this patient is not eligible for treatment with
trastuzumab and will receive vinflunine alone.

- Patients must have measurable disease not directly irradiated as per RECIST criteria.

- Measurable disease- is defined as at least one lesion that can be accurately measured
in at least one dimension (longest diameter to be recorded) as >20 mm with
conventional techniques or as >10 mm with spiral CT scan. See section 10.0 for the
evaluation of measurable disease.

- Prior Therapy: Chemotherapy: metastatic breast cancer. Patients must not have
received prior chemotherapy in the metastatic breast setting. Patients who have not
received prior anthracyclines or taxanes should be considered for these agents.
Chemotherapy: early stage breast cancer. Patients may have received prior
chemotherapy and/or hormonal therapy for early stage breast cancer. The chemotherapy
regimen may have included an anthracycline and/or a taxane as long as it has been > 6
months since completion of the regimen. Adjuvant trastuzumab is allowed. Radiation
therapy. Patients may have received prior radiation therapy in either the metastatic
or early stage setting as long as <25% of the bone marrow has been treated. Prior
radiation to the whole pelvis is not allowed. Radiation therapy must be completed at
least 7 days prior to study registration, and all radiation related toxicities must
be resolved to grade ≤ 1 before patient is eligible for study inclusion. Hormonal
therapy. Patients may have received any number of hormonal therapies in the
neo-adjuvant, adjuvant or metastatic setting. Patients must discontinue hormonal
therapy at least one week prior to starting study treatment.

- Age >18 years. Only women are eligible for the study.

- Life expectancy of > 6 months.

- ECOG performance status <2.

- Patients must have normal organ and marrow function as defined below. Laboratory
tests should be completed within 14 days prior to starting study treatment. Only for
patients who will be receiving trastuzumab, a left ventricular ejection fraction
(LVEF) may be determined by either echocardiography or MUGA scan, and should be
obtained within 4 weeks prior to starting study treatment.

- ANC >1,500/µl

- Platelets >100,000/µl

- Hgb > 10 g/dL

- Total bilirubin within normal institutional limits

- AST (SGOT) or ALT (SGPT) <5.0 X institutional ULN (for patients with liver
metastasis) <3.0X institutional ULN (for patients without liver metastasis)

- Creatinine < 1.5 mg/dl x ULN

- Calcium <1.2 x ULN

- LVEF > 50%

- Concurrent Therapy. Patients may not receive concurrent hormonal therapy,
chemotherapy, or radiation treatments while on study. Patients who develop brain
metastases during protocol-based treatment will be recorded as having progressive
disease on therapy and will be taken off study. Patients may not receive other
experimental treatments while on study.

- Fertility/reproduction. Patients must not be pregnant, expect to become pregnant or
conceive a child from time of first signing study consent until at least 12 weeks
after last dose of study treatment. The effects of trastuzumab and vinflunine on the
developing human fetus at the recommended therapeutic dose are unknown. For this
reason, women of childbearing potential must agree to use a method of contraception
that is acceptable to their physicians from time of first signing study consent until
at least 12 weeks after the end of drug administration. Should a woman become
pregnant or suspect she is pregnant while participating in this study, she should
inform her treating physician immediately.

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

- Patients who have not recovered to < grade 1 toxicity due to prior chemotherapy (for
early stage breast cancer) or prior radiation therapy are not eligible for study.

- Patients who have received prior vinca alkaloid chemotherapy are not eligible unless
treatment was completed > 5 years ago.

- Patients in which the HER2 status is unknown or is FISH negative will not receive
trastuzumab but are eligible for treatment with single agent vinflunine.

- Patients that have received prior chemotherapy for metastatic breast cancer.

- Patients receiving trastuzumab must have received a cumulative dose of doxorubicin
less than 360mg/m2, and/or an epirubicin cumulative dose less than 720mg/m2 for study

- Patients with known leptomeningeal carcinomatosis are excluded from this clinical
trial because of their poor prognosis and because they often develop progressive
neurologic dysfunction that would confound the evaluation of neurologic and other
adverse events. Patients with brain metastasis can participate if they have undergone
appropriate treatment, are at least 1-month post treatment, have no significant
neurologic symptoms, and are not on steroids. Screening for CNS disease is not
required if patients do not have symptoms that might be related to CNS metastasis.
Patients with such symptoms should be evaluated for the possibility of CNS disease
prior to study participation.

- History of grade 3 or 4 allergic reactions attributed to trastuzumab. Patients who
experienced grade 1 or 2 hypersensitivity reactions to prior trastuzumab therapies
are eligible if these reactions did not prevent further administration of such
agents. Patients in whom trastuzumab is contraindicated but whose tumor expresses
HER2, may be entered and treated with vinflunine alone. These patients will be
evaluated on the non-trastuzumab arm.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women are excluded from this study because the study drugs are agents that
may have the potential for teratogenic effects. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with these drugs, breastfeeding should be discontinued if the mother is
treated on study.

- History of other non-breast cancer malignancy except for carcinoma in situ of the
cervix or non-melanoma skin cancer, or in patients with greater than a 5-year disease
free interval from a prior malignancy.

- Patients may not receive other investigational agents while on study.

- Patients who have received prior chemotherapy for early stage breast cancer with the
completion of the regimen being < 6 months will not be eligible.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

overall response rate

Outcome Time Frame:

18 months

Safety Issue:


Principal Investigator

Denise A Yardley, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

January 2006

Completion Date:

November 2010

Related Keywords:

  • Breast Neoplasms
  • Breast Cancer
  • Breast Neoplasms
  • Breast Cancer
  • Vinflunine
  • Vinca Alkaloid
  • Javlor
  • Breast Neoplasms
  • Neoplasms



Northeast Alabama Regional Medical CenterAnniston, Alabama  36207
Florida Cancer SpecialistsFort Myers, Florida  33901
Northeast Georgia Medical CenterGainesville, Georgia  30501
Spartanburg Regional Medical CenterSpartanburg, South Carolina  29303
Integrated Community Oncology NetworkJacksonville Beach, Florida  32250
Grand Rapids Clinical Oncology ProgramGrand Rapids, Michigan  49503
Hematology Oncology Life CenterAlexandria, Louisiana  71301
Tennessee OncologyNashville, Tennessee  37203
Watson Clinic Center for Cancer Care and ResearchLakeland, Florida  33805
Associates in Hematology OncologyChattanooga, Tennessee  37404